What Vexed Top Global Biopharmaceutical Executives About COVID-19 Response
Executive Summary
Pfizer, Eli Lilly and Roche bosses say no country was perfect in its response to the coronavirus pandemic and there are lessons to be learnt.
You may also be interested in...
Global Biopharma CEOs Frustrated By IP Waiver Talk Amid COVID-19 Vaccine Glut
Top pharma executives claim ongoing vaccine inequity is not due to a lack of supply but to a shortage of sufficient infrastructure in low-and-middle income countries to administer available doses.
Coronavirus Notebook: Hearings On Pandemic Treaty Begin, New Risk-Sharing Partnership To Boost COVAX Efforts
Médecins Sans Frontières says the latest draft of the proposed IP waiver must be rejected, and the WHO has suspended supply of Bharat’s COVID-19 vaccine over manufacturing issues. Two EU agencies have issued advice on fourth doses of mRNA vaccines, while GlaxoSmithKline has filed high-dose sotrovimab for patients with suspected Omicron BA.2 infection in Australia.
How Biotech Firms Kept Raw Material Shortages From Affecting Patients During Pandemic
Biogen, Amgen, Lilly and Genentech experts shared tales of impending stockouts, particularly for single-use assemblies, filters and resins, and some of the measures they took to prevent them from causing drug shortages.